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The protein CrV2 is encoded by a polydnavirus integrated
into the genome of the endoparasitoid Cotesia rubecula
(Hymenoptera:Braconidae:Microgastrinae) and is expressed in
host larvae with other gene products of the polydnavirus to
allow successful developmentof theparasitoid.CrV2expression
has previously been associated with immune suppression,
although the molecular basis for this was not known. Here, we
have used time-resolved Fo¨rster resonance energy transfer (TR-
FRET) to demonstrate high affinity binding of CrV2 to G sub-
units (but not theGdimer) of heterotrimericG-proteins. Sig-
nals up to 5-fold above background were generated, and an
apparent dissociation constant of 6.2 nM was calculated. Prote-
ase treatment abolished the TR-FRET signal, and the presence
of unlabeled CrV2 or G proteins also reduced the TR-FRET
signal. The activation state of the G subunit was altered with
aluminum fluoride, and this decreased the affinity of the inter-
action with CrV2. It was also demonstrated that CrV2 preferen-
tially bound toDrosophilaGo comparedwith ratGi1. In addi-
tion, three CrV2 homologs were detected in sequences derived
from polydnaviruses fromCotesia plutellae andCotesia congre-
gata (including the immune-related early expressed transcript,
EP2). These data suggest a potential mode-of-action of immune
suppressors not previously reported, which in addition to fur-
thering our understanding of insect immunity may have practi-
cal benefits such as facilitating development of novel controls
for pest insect species.
Polydnaviruses (PDVs)2 are endogenous particles that are
produced by some parasitoidwasps and injected, alongwith the
wasp egg(s), into the hemocoel of host insects causing a range of
developmental and immune effects that allow the parasitoid to
successfully develop (1–4). Members of the Polydnaviridae are
divided into two paraphyletic groups as follows: bracoviruses
(BVs; genus Bracovirus) and ichnoviruses (genus Ichnovirus),
which occur in somemembers of the wasp families, Braconidae
and Ichneumonidae, respectively (5). Recent evidence suggests
that these genera should perhaps be placed into separate virus
families, as there is good evidence that Bracovirus and Ichnovi-
rus derived from different ancestral viruses (6, 7). PDVs are
replicated only in the ovaries of female wasps and are not
known to affect the wasp (8). PDVs are highly unusual in that
individual particles only contain a subset of the expressed genes
and do not contain any genes for virus structure/replication.
Therefore, the virus is only able to be transmitted vertically
(betweenwasp generations) through the integration of the PDV
genome into wasp chromosomes (8–10). Indeed, it was the
analysis of nonpackaged PDV genes (such as capsid proteins)
that allowed the different ancestral viruses to be differentiated.
Prior to this, a range of encapsidated PDV genes and/or gene
families was postulated as being immune-suppressive, target-
ing cellular and humoral (cell-free) aspects of the innate insect
immune system (4). Proteins encoded by these genes include
protein-tyrosine phosphatases (11), viral ankyrins (vankyrins)
(12, 13), host translation inhibitory factors (14, 15), EGF-like
proteins (16), CrV1 homologs (17–19), EP1-like proteins (20),
the H4 histone (21), and C-type lectins (22–25). Other PDV
proteins are also thought to target insect immunity, but as yet
their class and potential mode-of-action are yet to be eluci-
dated. CrV2, expressed by the Cotesia rubecula bracovirus
(CrBV), is an example of such a protein. CrV2 is expressed by
CrBV only in the larvae of two closely related butterflies (Pieris
spp.) and is secreted into the hemolymph. It was thought to be
temporally associatedwith short term, subtle immune dysfunc-
tion in hemocyte cells that take up the secreted protein,
although themolecular basis for its effects is not yet understood
(26). The protein does not cause toxic effects on the cells that
recover their immune function once significant expression of
CrV2 (and other early expressed proteins) is reduced. Here, we
present data that infer a specific, high affinity interaction
between CrV2 and invertebrate/mammalian G subunits of
heterotrimeric G-proteins, which are important cell-signaling
proteins, indirectly implicated in vertebrate and invertebrate
immune function (see under “Discussion” and Refs. 27–32).
Heterotrimeric G-proteins consist of three subunits, the G
subunit and a dimer of G and G (G). There are a variety of
subtypes for each G-protein class. The G subunit binds gua-
nine nucleotides and exchanges GDP for GTP upon activation
of the G-protein-coupled receptor (GPCR) with which the
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G-protein is usually associated. Nucleotide exchange causes
conformation changes such that the G subunit and the G
dimer interact with downstream effectors, including various
enzymes and ion channels that alter cellular metabolism (33).
We previously developed a TR-FRET (time-resolved Fo¨rster
resonance energy transfer) assay utilizing a terbium-chelate
donor and Alexa546 acceptor to demonstrate interactions of
theG subunit with theG dimer and the regulator of G-pro-
tein signaling 4 (RGS4) (34). The assay was recently adapted by
others tomonitor the effect of allosteric modulators of RGS4 in
altering RGS4:G affinity and further developed into a high
throughput screen for other such modulators (35). Generally,
TR-FRET uses a lanthanide donor fluorophore (such as ter-
bium or europium) in combination with an appropriate accep-
tor (with an excitation spectrum overlapping the donor emis-
sion spectrum). When the fluorophores are in close proximity
(100 Å), energy transfer occurs between them, and acceptor
emission is measured to determine binding kinetics (36). Using
a lanthanide donor increases the signal:noise ratio when the
long lived luminescence (characteristic of lanthanides) is
exploited with time-gated measurements that eliminate short
lived background signals. Lanthanides also exhibit other favor-
able properties, including multiple emission peaks, a large
Stokes shift, and nonpolarized emission (37, 38).
As part of validating the original TR-FRET assay, we deter-
mined that the CrV2 protein appeared to specifically interact
with mammalian G subunits. Here, we adapt our TR-FRET
assay to demonstrate a high affinity (nanomolar) interaction of
acceptor-labeled CrV2 with mammalian and insect donor-la-
beledG.We also demonstrate that recombinantCrV2 is taken
up by a specific hemocyte morphotype from larval Pieris rapae,
which are key immune cells, where it could potentially interact
with cellular proteins such asG. These results are intriguing as
they suggest that insect hemocyte immune function could be
regulated through G-protein signaling pathways and that some
PDVs subvert host immunity by producing proteins that inter-
act withG to alter immune signaling. Thismode-of-action for
immune suppression has not previously been reported, and its
elucidation has the potential to facilitate the development of
novel insect controls.
EXPERIMENTAL PROCEDURES
All chemicals and reagents were of analytical grade and pur-
chased from Sigma unless otherwise stated. All buffers were
made in Milli-Q water.
Production and Purification of Recombinant CrV2 and
G-protein Subunits—To produce CrV2 used in cell and far
Western blot experiments, PCR was used to generate full CrV2
constructs containing the N-terminal signal peptide with a His
tag incorporated at the 3 end and NotI and KpnI restriction
enzyme sites at the 5 and 3 ends, respectively. The forward
primer sequence was 5-gcg gcc gca tgt tgt cta caa agc-3, and
the reverse primer sequencewas 5-ggt acc tta gtg atg gtg atg gtg
atg ggg atg atc tcg agc cct-3. PCR products were producedwith
proofreading polymerase and cloned into pCR-Blunt (Invitro-
gen) to allow subsequent restriction of the cloned products for
insertion into pFastBac1 (Invitrogen). Recombinant baculovi-
rus was then generated using the Bac-to-Bac system (Invitro-
gen) as per the manufacturer’s instructions. Sf9 cells at 2 106
cells/ml were infected with amplified virus at a multiplicity of
infection of2 for 48–72 h in suspension at 27 °Cwith shaking.
Cells were harvested by centrifugation, and expression was
confirmed by Western blot. The media containing secreted
CrV2 were stored at20 °C or80 °C for longer term storage.
To produce purified recombinant CrV2 for TR-FRET
experiments, the coding sequence without the first 21 N-ter-
minal amino acids, which contain the secretory signal pep-
tide, was cloned into pQE30 (Qiagen) and transformed into
M15[pREP4] Escherichia coli as per Glatz et al. (26). Expression
of recombinant CrV2 was induced in 400-ml bacterial cultures
in YT broth (8 g/liter tryptone, 5 g/liter yeast extract, 2.5 g/liter
NaCl, pH 7.0) as per the manufacturer’s instructions. Induced
bacterial cells were pelleted by centrifugation and stored at
80 °C. Cells were later resuspended in 10ml of TBP buffer (50
mM Tris, pH 8, 10 mM -mercaptoethanol, 0.02 mg/ml phenyl-
methanesulfonyl fluoride, 0.03mg/ml benzamidine). Lysozyme
was added to a final concentration of 0.2 mg/ml and gently
mixed at 4 °C for 30 min. MgCl2 was then added to a final con-
centration of 5 mM followed by DNase I to a concentration of
0.01mg/ml.Mixingwas continued for a further 30min. Twenty
percent (w/v) cholate solution (50 mMNaHEPES, pH 8.0, 3 mM
MgCl2, 50 mM NaCl, and 200 g/liter cholic acid (Na)) was
added to give a final cholate concentration of 1% (v/v). The
preparation was then gently stirred (1 h at 4 °C) before ultra-
centrifugation in a Beckman Coulter OptimaTM LE-80K at
100,000  g for 40 min. Ni-NTA-agarose beads (800 l; Qia-
gen) inTBP (50%)were added to the supernatant and incubated
on ice for 30 min with occasional stirring. Supernatants were
then applied to gravity-fed columns. Columns were then
washedwith 20ml of TBP containing 100mMNaCl followed by
washing with 5 ml of TBP containing 100 mM NaCl and 10 mM
imidazole. All washing procedureswere carried out at 4 °C.His-
tagged CrV2 was eluted from the column in 400-l fractions
using TBP containing 100 mM NaCl and 250 mM imidazole.
Elution fractions were run on a polyacrylamide gel and stained
using Coomassie Blue. Elutions containing CrV2 were identi-
fied and fractions pooled. Protein concentration was deter-
mined according to Bradford (39) or by laser densitometry,
before aliquoting and storage at80 °C.
G-protein subunits were produced from 1 to 2 liters of Sf9
cells infected with the desired recombinant baculovirus.
Recombinant full-length Drosophila Go (isoform I)-express-
ing baculovirus was produced using the Bac-to-Bac expression
system as described by the manufacturer (Invitrogen). Cell cul-
ture, virus amplifications, and infections, as well as the purifi-
cation of G-protein subunits using Ni-NTA-agarose beads and
fluorescent labeling of G-proteins or CrV2 with cysteine-reac-
tive Alexa Fluor 546 C5-maleimide (Invitrogen) or CS124-
DTPA-EMCH-Tb (Invitrogen), were performed as described
by Leifert et al. (34).
Antibody Labeling of CrV2 in Hemocytes in Vitro—Larval P.
rapae were surface-sterilized in ice-cold 70% ethanol for a few
minutes and then kept on ice until they were bled from a sev-
ered proleg directly into an ice-chilled 1.5-ml microcentrifuge
tube containing200 l of Sf900II medium (Invitrogen) satu-
rated with phenylthiourea (which inhibits melanization reac-
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tions). Hemocytes were aliquoted into wells of a printed glass
slide and incubated at room temperature until cells attached,
and spreading was observed. Obviously, spread cells were con-
sidered to be a plasmatocyte morphotype and attached cells
that retained a rounded, apparently unspread, conformation
were considered as a granulocyte morphotype. Insect cell cul-
ture medium containing secreted baculovirus-expressed CrV2
was applied to the hemocyte-containing slides and incubated
for the desired time.Mediumwas then removed, and cells were
fixed in 4% paraformaldehyde for 15 min, permeabilized with
0.1% Triton X-100 for 4 min, and washed in TBST (8.8 g/liter
NaCl, 0.2 g/liter KCl, 3 g/liter Trizma (Tris base), 500 l/liter
Tween 20 detergent). Anti-CrV2 polyclonal rabbit antibodies
(26) inTBST (1:500)were added to the glass slide and incubated
for 1.5–2 h at room temperature. Cells werewashedwithTBST,
and fluorphore-conjugated anti-rabbit antibody (1:200–250)
with 1:50 dilution of FITC-phalloidin (0.1 mg/ml) in TBST
were applied to slides for 1 h at room temperature in the dark.
Cells were then washed with TBST and stained with 1:10,000
dilution (1 g/ml) of DAPI for 5 min. Cells were then washed
with TBST and PBS; a coverslip was applied, and the coverslip
sealed with nail varnish.
TR-FRET Assays—The interaction between Alexa546 (Alexa)-
and CS124-DTPA-EMCH-Tb (Tb)-labeled proteins was mea-
sured using TR-FRET as described in Leifert et al. (34). Briefly,
these experiments were conducted in black 96-well plates. 20
working solutions of proteinsweremade inTMNbuffer (50mM
Tris, pH 7.6, 100 mM NaCl, 10 mM MgCl2). Five microliters of
each was then applied to opposite sides of the well such that
mixing did not occur.Other indicated components such as pro-
teinase K could also be added in this manner where required.
TMN buffer was then added to give a final assay volume of 100
l, and the reaction was initiated by mixing of all components.
TR-FRET was then measured using a Victor3 multilabel plate
reader (PerkinElmer Life Sciences) using an excitation wave-
length of 340 nm and a delay of 50 s, before measuring the
emission at 572 nm for 900 s. Where appropriate, measure-
ments were ceased so that unlabeled proteins or buffer could be
added and then measurements resumed.
[35S]GTPS Binding Assay—40 nM purified G subunit or
CrV2 wasmixed with 1 nM [35S]GTPS in a final volume of 100
l of TMN buffer and incubated in a shaking water bath for 90
min at 27 °C. Twenty five microliters in triplicate were then
filtered through glass microfiber 1-m filter papers (GFCs;
Filtech), and unbound [35S]GTPS was removed by washing
with three times with 4ml of TMNbuffer. The filters were then
dried, and the amount of bound [35S]GTPS was measured by
scintillation counting for 60 s in Pico Pro VialsTM with 4 ml of
Ultima GoldTM scintillation mixture (PerkinElmer Life Sci-
ences) using a Wallac 1410 liquid scintillation counter.
Far Western Assay—Purified Drosophila Go and bovine
serum albumin were subjected to SDS-PAGE on an “any kDa”
TGXgel (Bio-Rad) using a nonreducing sample buffer. Proteins
were transferred onto a Hybond-C nitrocellulose membrane
(GEHealthcare) at 100V for 1 h.Membraneswere blockedwith
5% skim milk powder in TBS buffer (8.8 g/liter NaCl, 0.2g/liter
KCl, 3 g/liter Trizma) for2 h. Membranes were then probed
with CrV2 in Sf900II medium or conditioned medium over-
night. Membranes were then washed with TBST buffer (see
above) and probed with rabbit anti-CrV2 (1:10,000) in blocking
solution for 2 h. Following washing with TBST, membranes
were probed with alkaline phosphatase-conjugated goat anti-
rabbit IgG (1:20,000) in blocking solution for 2 h. Membranes
were washed with TBST and developed using 5-bromo-4-
chloro-3-indolyl phosphate p-toluidine salt and nitro blue tet-
razolium chloride to detect any CrV2 bound to Go.
TR-FRET Data Analyses—Data were analyzed using PrismTM
4.00 (GraphPad software Inc., SanDiego). Data are presented as
mean  S.E., where n is equal or greater than 3. Where n 	 2,
data are presented as the mean, and error bars represent the
range of the duplicates. If error bars are not visible, they are
small and therefore hidden by the symbols.
Amino Acid Sequence Analyses—The CrV2 amino acid
sequence was subjected to protein Blast (blast.ncbi.nlm.nih.
gov) to detect any similar protein sequences. Three similar
sequences were detected. ClustalW2 software was then used
to align the amino acid sequences of the four similar proteins
and to produce a simple phylogenetic tree of the four protein
sequences. Protein BLAST was also used to determine the
amino acid identity between the two experimental G sub-
units used here, i.e. rat Gi1 (GenBankTM accession number
NP_037277) and Drosophila melanogaster Go isoform I
(GenBankTM accession number AAS64873).
RESULTS
Identification of CrV2 Homologs—CrV2 amino acid se-
quence was subjected to protein Blast, resulting in detection of
three similar amino acid sequences, which are putative
homologs (Fig. 1). One sequence (EPL-7) is a hypothetical pro-
tein determined from the genome sequence ofCotesia plutellae
bracovirus (CpBV). The other two proteins are derived from
the Cotesia congregata bracovirus (CcBV); One of these en-
codes the early expressed immune suppression-related tran-
script, EP2 (40), and the second is a hypothetical protein
CcBV_31.9 derived from the total CcBV genome sequence.
ClustalW2 software was used to align the amino acid sequences
of the four proteins.
Uptake of CrV2 by Hemocytes—Application of hemocytes to
thewells of a glass slide results in adherent cells attaching to the
slide surface. A subpopulation of cells was then observed to
spread, although other cells remain more rounded. These cells
are considered as plasmatocytes and granulocytes, respectively.
CrV2 was only detected in association with the unspread,
rounded cells following incubation of all hemocytes with CrV2
(Fig. 2). These results suggest that CrV2 is likely to modulate
some function of granulocytes while not directly affecting plas-
matocytes. However, apart from the uptake of CrV2, the effect
on granulocytes produced no other phenotype observable
under our conditions.
Interaction of CrV2 with Gi1 Measured by TR-FRET—Re-
combinant bacterially expressedCrV2was successfully purified
using Ni-NTA chromatography, and the protein was labeled
with the fluor Alexa546. G-protein subunits were expressed in
Sf9 cells and also purified using Ni-NTA chromatography.
These terbium-labeled (or unlabeled) G-proteins were func-
tional in receiving signals from appropriate GPCRs in a recon-
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stituted system as shown by Leifert et al. (34). Purified CrV2
labeled with Alexa546 (CrV2-Alexa) as the acceptor for TR-
FRET, was mixed with purified Gi1 labeled with CS124-
DTPA-EMCH-Tb (Gi1-Tb) as the fluorescent donor exhibit-
ing long lived luminescence. Upon mixing of the two labeled
proteins and excitation of terbium at 340 nm, an increase in
gated emission of Alexa546 (acceptor) fluorescence at 572 nm
occurred with time. Signals up to 5-fold greater than the back-
ground could be achieved and the signal increased upon addi-
tion of increasing amounts of CrV2-Alexa (Fig. 3A). Back-
ground fluorescencewas generated by a low amount ofGi1-Tb
emission in the 572 nm channel, whereas background contri-
butions fromAlexa546 and other buffer components were neg-
ligible because typical autofluorescence had decayed during the
50-s delay (after excitation) before the emission signal was
measured. When increasing concentrations of CrV2-Alexa
were added to 10 nM Gi1-Tb, saturation was achieved at 25
nM CrV2-Alexa, and an apparent dissociation constant (Kd) of
6.2 nMwas produced (Fig. 3B). This indicated that a high affinity
interaction was occurring between CrV2-Alexa and Gi1-Tb,
whichwas comparablewith the affinity between theG subunit
and the G dimer (2 nM) measured using the same technique
(34). To show the TR-FRET signal was attributable to a specific
protein/protein interaction, proteinase K, a broad spectrum
serine protease that cleaves peptide bonds at the carboxylic
sides of aliphatic, aromatic, or hydrophobic amino acids, was
used to digest the proteins. This reduced the TR-FRET signal
(Fig. 3C) and suggested that generation of the TR-FRET signal
was due to a specific interaction between complete CrV2 and
Gi1 proteins, which were destroyed by protease digestion.
The addition of an excess of unlabeled binding partners,
including Gi1 or CrV2 (Fig. 4, A and B, respectively), rapidly
FIGURE 1. A CrV2 gene family exists in Cotesia-associated bracoviruses. ClustalW2 software was used to align CrV2 against three putative homologs
detectedviaproteinBlast. Aminoacidnumbers arepresentedat theendof each lineof sequence. Proteins are as follows: EPL-7,hypothetical protein fromCpBV
genome sequence (GenBankTM accession number ABK63352), CrV2, CrV2 expressed by CrBV (GenBankTM accession number AY631272); EP2, EP2 expressed by
CcBV (GenBankTM accession number AJ632305), CcBV_31.9, putative protein from CcBV genome sequence (GenBankTM accession number YP184881). The
alignment is presented in order of increasing size of the first deletion common to three genes but is absent from hypothetical EPL-7 protein. There is another
conserved deletion downstreamof the first (relative to hypothetical EPL-7 protein) in the central region of the protein. The high level of conservation indicates
that the four genes are homologous. Consensus symbols follow convention of ClustalW2 software: *	 complete conservation; :	 conserved substitution; .	
semi-conserved substitutions.
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decreased the TR-FRET signal, although with the addition of
buffer, the signal remained steady. This further showed that a
specific interaction between the proteins was occurring (i.e.
reducedTR-FRETwas not the result of increased assay volume)
resulting in a significant TR-FRET signal because unlabeled
CrV2 orG appeared to compete for binding to labeled binding
partners. G42 could also inhibit the association of G-Tb
with CrV2-Alexa (Fig. 4C), and this was particularly interesting
because assuming that CrV2 does not bind to G, this could
suggest that G and CrV2 have overlapping binding sites on
the Gi1 subunit and/or disrupts the binding of the other. To
gain an insight as to whether CrV2 could also be associating
with theGdimer, CrV2-AlexawasmixedwithG42 labeled
with terbium (G-Tb). However, this failed to produce a sub-
stantial TR-FRET signal comparedwith that generated byCrV2
and Gi1 or Gi1 and G (Fig. 5). Although the labeling effi-
ciency of the G subunits with terbium may differ from G,
the similar level of background terbium luminescence sug-
gested that the amount of terbium present was not significantly
less and did not result in the lack of TR-FRET signal. This was
further established by the strong TR-FRET signal generated
from the interaction of G-Tb with Gi1-Alexa. The activa-
tion state of theG subunit could alsomodulate the interaction
with CrV2. The addition of excess GDP (or GTPS; data not
shown) produced similar association curves over time, whereas
the addition of aluminum fluoride (AlF3) by adding 10mMNaF
and 30 M AlCl3 appeared to decrease the maximum fluores-
cence achieved (Fig. 6).
Because insect G subunits would likely be the target for
CrV2 in vivo and show relatively little variation between differ-
ent organisms and G subclasses, we used the TR-FRET assay
to compare the CrV2/G interaction using Drosophila Go.
FIGURE 2.Uptake of CrV2 by specific P. rapae hemocytes. Pieris larvae were bled intomedia saturatedwith phenylthiourea; the hemocytes were applied to
the wells of a glass slide and allowed to adhere and spread. CrV2 in media was then applied to the cells and incubated for 45 min. A,merged image of bright
field and red fluorescence from TRITC secondary antibody bound to anti-CrV2 shows CrV2 associatedwith the small round hemocytes. B,merged blue and red
fluorescence images showing the nucleus (blue) stained with DAPI and CrV2 (red). C,merged blue, red, and green fluorescent image showing the nucleus (blue),
CrV2 (red), and the cytoskeleton stained with FITC-conjugated phalloidin (green).
FIGURE 3. CrV2-Alexa association with Gi1-Tb increases TR-FRET to saturation, and treatment with proteinase K abolishes TR-FRET. TR-FRET mea-
surementswere taken using a Victor3 plate reader set for time-resolved fluorescencewith the following parameters: ex 340 nm, em 572 nm, 50-s delay. and
900-s counting duration. A, 10 nM Gi1-Tb (f) wasmixedwith 20 nM (Œ), 40 nM (F), or 100 nM () CrV2-Alexa. Data shown aremean (n	 2). B, 10 nM Gi1-Tb
was mixed with increasing concentrations (0–40 nM) of CrV2-Alexa, and TR-FRET was measured following 10 min of incubation. The background from 10 nM
Gi1-Tb has been deducted, and an apparent dissociation constant (Kd) of 6.2 nM was calculated. Data shown are mean S.E. (n	 3). C, 10 nM Gi1-Tb was
mixed with 20 nM CrV2-Alexa 0.1 mg/ml proteinase K. After an incubation period of 30 min at 37 °C, TR-FRET measurements were taken. Data shown are
mean S.E. (n	 3) of the ratio of acceptor emission: donor emission.
In Vitro Interaction of CrV2with G
10470 JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 286•NUMBER 12•MARCH 25, 2011
 at UQ Library on October 5, 2016
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
Protein Blast showed that there is 69% amino acid identity
between the two experimental G proteins, rat Gi1 and Dro-
sophila Go isoform I. Recombinant baculovirus-expressed
DrosophilaGowas purified (Fig. 7A) and shown to be similarly
functional in binding [35S]GTPS as ratGi1, whereasCrV2did
not bind significant amounts of [35S]GTPS (Fig. 7B). This was
a good indication that a functionalDrosophilaGo subunit had
been expressed and purified from Sf9 cells. Fig. 7C shows that
when increasing concentrations of purified unlabeled G sub-
units were added to the TR-FRET assay of CrV2/Gi1 interac-
tions, Drosophila Go competed for binding to CrV2-Alexa at
lower concentrations than unlabeledmammalian Gi1, with an
IC50 of 41 nM compared with 241 nM. This indicated that Dro-
sophila Go had a higher affinity for CrV2 than mammalian
Gi1 and was the preferred binding partner of the two tested
subunits.
Interaction of CrV2 with Go Confirmed by FarWestern Blot—
To confirm the specific interaction observed by TR-FRET, Go
was blotted onto a nitrocellulose membrane and was labeled by
probing with recombinant CrV2, and then bound CrV2 was
detected with anti-CrV2 (Fig. 8). A range of results producing
no detection indicated the blotted Go was only detectable due
to prior CrV2 binding, viz. G was not detected when CrV2
was absent or when anti-CrV2 was not applied. Further-
more, CrV2 did not bind to bovine serum albumin under the
same conditions.
DISCUSSION
CrV2 Homologs—The detection of CrV2 homologs in the
genomic sequences of CcBV and CpBV indicates that there is
a family of CrV2-related proteins that are expressed by Cote-
sia-associated PDVs (Fig. 1). Two of the proteins (EPL-7 and
CcBV_31.9) are hypothetical, and their sequences were
directly translated from total virus genome sequences. The
third is the confirmed transcript EP2, which like CrV2 tran-
scripts was detected soon after parasitization and is thought
to be immune-suppressive (26, 40). Relative to the hypothet-
ical EPL-7 protein, the other homologs have two conserved
deletions occurring within the first 100 amino acids of the
respective proteins.
Each of the four homologs have identifiable, highly con-
served secretion signals (containing a high proportion of hydro-
phobic amino acids) at their N termini and are predicted to be
glycosylated; secreted CrV2 is also detected in large amounts in
the hemolymph of parasitized larvae (26, 40). It is therefore
likely that likeCrV2, all of the homologswould be secreted from
FIGURE 4. Unlabeled binding partners compete with Gi1-Tb for binding to CrV2-Alexa. TR-FRET measurements were taken with the following parame-
ters: ex 340 nm, em 572 nm, 50-s delay, and 900-s counting duration. A, unlabeled Gi1 competes for binding to CrV2-Alexa reducing the TR-FRET signal.
B, unlabeled CrV2 competes for binding to Gi1-Tb reducing the TR-FRET signal. A and B, 10 nM Gi1-Tb was mixed with 20 nM CrV2-Alexa in 100 l of TMN
buffer. At 5min, 2M of unlabeled Gi1 or 70 nM of unlabeled CrV2 (f) or an equivalent volume of TMNbuffer (Œ) was added and TR-FRETmeasurements over
the timeperiod shown. Backgrounds of 10nMGi1-Tbwith buffer added at 5min (F) and 10nMGi1-Tb the indicatedunlabeledprotein () are shown.Data
shown aremean (n	 2). C,G42 inhibits CrV2-Alexa association with Gi1-Tb. 10 nM Gi1-Tb wasmixedwith 20 nM CrV2-Alexa with or without 240 nM G42
in 100l of TMN buffer. Backgrounds of Gi1-Tb and Gi1-Tb G42 have been deducted as appropriate. Data shown are mean (n	 2). a.u., arbitrary units.
FIGURE5.CrV2-Alexa interactsonlyminimallywithG-Tb.10nMG-Tb
wasmixedwith 20 nMCrV2-Alexa or 10 nMGi1-Alexa to a final volume of 100
l with TMN buffer. TR-FRET measurements were taken with the following
parameters: ex 340 nm, em 572 nm, 50-s delay, and 900-s counting dura-
tion over the time period shown. Data shown are mean (n	 2).
FIGURE 6.Alteration of the activation state of Gi1 using aluminum fluo-
ride decreases the interactionwith CrV2. 10 nMGi1-Tbwasmixedwith 20
nM CrV2-Alexa with excess amounts of GDP (2.5 M) or aluminum fluoride
produced by the addition of NaF (10 mM) and AlCl3 (30 M). TR-FRET mea-
surements were immediately taken with the following parameters: ex 340
nm, em 572 nm, 50-s delay, and 900-s counting duration. Background of
Gi1-Tb with GDP or aluminum fluoride has been deducted. Data shown are
mean S.E. (n	 3). a.u., arbitrary units.
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infected cells. CrV2 protein was also detectable at 24 h post-
parasitization (by antibody staining of hemocytes andWestern
analyses of tissues and serum fromparasitized larvae). This is in
contrast to the CrV2 transcript, which had been reduced so as
to be undetectable by Northern hybridization as early as 12 h
post-parasitization (26, 41). The large amount of hemocyte-
related CrV2 protein at a time where high level expression is
not detected and corresponding (transient) loss of hemocyte
immune function, both suggested that these key immune cells
are the target for CrV2 (26).
CrV2 was also shown to exist as a trimer in the hemo-
lymph of infected larvae, and a C-terminal coiled-coil region
(starting approximately at amino acid 270) was predicted to
be responsible for the trimeric structure (26). This region is
again well conserved, with a large percentage of “redundant”
amino acid substitutions occurring between the homologs in
this region, indicating that each protein forms polymeric
structures in the hemolymph. Therefore, the key functional
region is likely to lie within the highly conserved central
parts of the amino acid sequence. This could be assessed by
generating mutants with targeted amino acid substitutions
in that region.
Specific Uptake of CrV2 by Granulocytes—Application of
CrV2 to hemocytes showed that CrV2 was taken up from sur-
rounding medium. Moreover, the recombinant protein was
only associated with a specific type of hemocyte that once
attached to the slide surface displayed a smaller, more rounded
morphology, typical of granulocytes. This suggests that CrV2
targets a particular immune function carried out by granulo-
cytes, which may not occur in plasmatocytes. Infection with
PDVs has previously been observed to have effects on a single
hemocyte type. Interestingly, Strand and Pech (42) reported
thatMicroplitis demolitor bracovirus induced apoptosis specif-
ically in granulocytes. However, to date our studies have not
shown that the presence of CrV2 results in apoptosis, and apo-
ptosis has not been observed in the Cotesia-Pieris system.
Specific in Vitro Interaction between CrV2 and G—In this
study, we used an established in vitroTR-FRET assay (34, 35) to
identify a novel interaction between the G-protein subunit G,
and CrV2. We demonstrated that CrV2 binds to G subunits
from rat andDrosophila, with nanomolar affinity (Kd	 6.2 nM).
Far Western analysis also confirmed the presence of a specific
interaction with Drosophila Go. There are relatively few
proven/proposed G-binding proteins, and these proteins gener-
ally have affinities in the nanomolar range. For example, the
TR-FRETassay usedherewas previously applied to calculateKd
values of 2.4 and 14.6 nM for the interaction of Gi1 with G
and RGS4, respectively (34). Other assays have produced com-
parable results, the mammalian G/Gi1 interaction was
shown to have a Kd of 3 nM using flow cytometry (43). A regu-
lator of G-protein signaling, RGS4, was shown to interact with
GTP-activated Gq protein with a Kd of1 nM (44). Ozaki et al.
FIGURE 7.DrosophilaGo purified from Sf9 cells binds to [
35S]GTPS and competes for binding to CrV2. A, polyacrylamide gel showing eluted fractions
ofDrosophilaGo from 1.7 liters of infected cells purified using Ni-NTA chromatography. B, 40 nMG or CrV2wasmixedwith 1 nM [
35S]GTPS in a final volume
of 100 l of TMN buffer and incubated in a shaking water bath for 90 min at 27 °C. 25 l was then filtered through GFC filters, and unbound [35S]GTPS was
removed by washing with TMN buffer. The amount of bound [35S]GTPS was thenmeasured by scintillation counting. Data shown are mean S.E. (n	 6) of
filter triplicates of twoexperiments.C,CrV2-Alexabindspreferentially toDrosophilaGowhen20nMCrV2-Alexawasmixedwith20nMmammalianGi1-Tb and
doses (0–900 nM) of unlabeled Drosophila Go (f) or mammalian Gi1 () were added to compete with labeled proteins. TR-FRET measurements were taken
with the following parameters: ex 340 nm, em 572 nm, 50-s delay, and 900-s counting duration over the shown time period. Data shown aremean S.E.
(n	 3). a.u., arbitrary units.
FIGURE 8. Far Western blot confirms Go interaction with CrV2. A, Coo-
massie-stained gel of Go (right lane) run by SDS-PAGE with molecular
weight marker (Bio-Rad precision plus dual color protein standard) in left
lane. B, duplicate samples of A transferred to nitrocellulose and probed
with CrV2. CrV2 binding was detected using rabbit anti-CrV2 and alkaline
phosphatase-conjugated secondary antibody. CrV2 bound to the band of
Go but did not bind to BSA under the same conditions (data not shown).
Go was not detected when probe CrV2 or anti-CrV2 was absent (data not
shown).
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(31) used surface plasmon resonance on immobilized bovine
G-protein to calculate Kd values for the invertebrate proteins
tachyplesin and mastoparan (both discussed below) of 880 and
220 nM, respectively. Therefore, the high affinity of the
CrV2/G interaction (Kd 	 6.2 nM for rat Gi1) is highly
unlikely to occur through chance alone and suggests that the
interaction between G and CrV2 could also occur in vivo as
part of immune suppression by CrBV.
A specific interaction is also supported by the finding that the
CrV2/G interaction can bemodulated byAlF3, which changes
the conformation of the G subunit to mimic the “transition
state” (45, 46). This is similar to the association ofGwithG,
wherebyAlF3 causes dissociation of the subunits and a decrease
in TR-FRET signal and is in contrast to the result seen with
RGS4 where an increase in TR-FRET signal with G was
achieved in the presence of AlF3 (34). The decrease in signal
generated by the interaction of G with CrV2, upon the addi-
tion of AlF3, could be a result of the inability of CrV2 to bind to
G subunits in the transition state or, alternatively, a confor-
mational change in the bound CrV2/G complex resulting in
the donor and acceptor labels being moved further apart and
decreasing FRET efficiency (resulting in a lower signal). The
fact that AlF3 does not return the signal to background level
could indicate that conformational change or a decrease in
affinity is more likely than a complete loss of interaction. The
physiological importance of these data is unclear because
although commonly employed for this purpose within pub-
lished literature, the presence of AlF3 “mimics” an in vivo G
activation state; actual AlF3-activatedG proteins do not occur
in vivo.
It also appears that the binding site of CrV2 could overlap
with that ofG becauseG can competewithCrV2 for bind-
ing to G. This may also in part explain the effect of AlF3 in
decreasing the interaction between CrV2 and G because AlF3
changes the conformation of G in switch regions known to be
important for G binding (45, 46). The fact that CrV2 binds to
G subunits from rat andDrosophila is not particularly surpris-
ing as the two experimental proteins showed a high level of
amino acid identity (69%). Analyses of partial G amino acid
sequences from lepidopteran cell lines have shown that Gq
and Gi subtypes identical between the tested lepidopteran
species were between 88 and 98% identical to other inverte-
brates and 88 and 90% identical to knownmammalian subunits
(47). Similarly toCrV2, invertebrate proteinsmastoparan (from
Vespa spp. wasps) and tachyplesin (from the horseshoe crab,
Tachypleus tridentatus) are also known to bind to mammalian
G-proteins even though they interact with homologous inver-
tebrate proteins in vivo (31, 48). CrV2 had a higher affinity for
the Drosophila protein (Fig. 6C), which could be due to an
evolved preference for Go rather thanGi1 or the invertebrate
origin of the protein rather than the mammalian. Regardless of
the reasons for CrV2 interaction with mammalian G and the
preference for the tested Drosophila subunit, these data never-
theless suggest that there is physiological importance in the
CrV2 interaction with G subunits in insects. However, the
specific metabolic consequences of the interaction between
CrV2 and Gi1 require further investigation.
G-protein Relationship with Invertebrate Immunity—Why
would CrV2 target G? Most studies on G-protein-coupled
receptors, G-proteins, and their associated signal transduction
pathways have been conducted in mammalian organisms. In
mammals, G-proteins regulate various effectors, including
enzymes and ion channels to mediate processes in most bodily
systems, including the nervous, circulatory, and immune sys-
tems (49). G-proteins are also known to be important signaling
molecules in invertebrates, but as yet, the specific immune-
associated biochemical pathways and protein interactions have
not been elucidated. However, there is a range of evidence that
has indirectly linked invertebrate immunity and G-protein sig-
naling. For example, in the mollusc Mytilus galloprovinicialis,
corticotrophin-releasing hormoneGPCR subtypes are involved
with mediating cell shape changes in immunocytes through
G-protein pathways (50). Exocytotic responses that release
defense-related molecules from the intracellular stores of
hemocytes are an important part of the immune response of
invertebrates in detection of pathogens. The invertebrate Styela
plicata induces the release of such molecules through a G-pro-
tein pathwaywhere pharmacological reagents, known to inhibit
G-proteins and tubulin microtubule assembly, decreased the
release of C3-like proteins (51). Exocytosis has also been shown
to be regulated by G-protein subunits, including Gi, Go, and
G subunits (52, 53), and immune pathways are induced by
activating adenylate cyclases to produce cyclic AMP (or phos-
pholipases to produce inositol 1,4,5-trisphosphate and diacyl-
glycerol) and cause release of divalent cations to activate protein
kinases (27, 32), all of which are classical downstream effects of
G-proteins. A specific example is data showing that cAMP lev-
els are related to the immune responses of hemocytes in larval
lepidopteran insects (29).
There are also other examples of proteins from invertebrates
that interact with G-proteins to apparently modulate immune
responses. Tachyplesin (discussed above) is a major granular
component of hemocytes of the horseshoe crab and is an anti-
microbial peptide with broad spectrum activity against both
Gram-positive and -negative bacteria (30).Moreover, tachyple-
sin has been found to induce hemocyte exocytosis in a positive
feedback mechanism to amplify the immune response to an
infection through a G-protein signaling pathway and was also
demonstrated to interact directly with a bovine G-protein with
a Kd of 0.88 M (31, 54), which is relatively low in affinity com-
pared with the CrV2 interactions we propose here. A similar
process is likely to occur in other invertebrates, but as yet,
tachyplesin homologs have not been discovered. Tachyplesin
shares a number of structural similarities with the wasp venom
protein, mastoparan (see above), that has also been found to
regulate cellular responses by inducing exocytosis of substances
from mammalian cells such as histamine from rat mast cells,
serotonin from platelets, catecholamines from chromaffin cells
and prolactin from the anterior pituitary (48). As mentioned
previously, mastoparan was shown to directly interact with
bovine G-proteins (31) and also to increase the GTPase activity
and rate of nucleotide exchange to purified bovine Go inde-
pendently of a GPCR (48). Interestingly, mastoparan was also
associated with G-protein dysfunction leading to decreased
expression of genes associated with LPS-induced (i.e. bacteria-
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induced) responses of mammalian endothelial and immune
cells (28). This is interesting as it represents another example of
a wasp-derived protein that interacts with G-proteins from a
wide variety of organisms and is associated indirectly with
immune regulation.
Concluding Remarks—Here, we have provided evidence that
CrV2 accumulates in a specific type of hemocytewhere it would
be expected to modulate immune functions. The existence of
CrV2 homologs also suggests that CrV2 has an important role
in modulating host physiology that is conserved among a num-
ber of braconid species. We have also shown an in vitro inter-
action at physiologically relevant concentrations of CrV2 with
G subunits. Although there is indirect evidence that G-pro-
teins are involved in cellular immune cascades in invertebrates,
there have not been reports of potentially immune-suppressive
proteins that interact with G-proteins or their signaling cas-
cades. We therefore propose that CrV2 provides further evi-
dence of the involvement of G in insect immune signaling and
that the interaction between CrV2 and G could represent a
novel mode-of-action for immune suppression by PDVs, which
are known to express a range of immune-suppressive proteins
in parasitized insects (1, 3).
Given this combined evidence for G involvement in the
immune response of invertebrates, and the data we present
here showing nanomolar affinity between the proteins, we
hypothesize that CrV2 targets G subunits in specific im-
mune cells (granulocytes) to disrupt G-associated immune
signaling by these cells. This would likely produce an abro-
gation of normal immune processes such as exocytosis. Fur-
ther work establishing the interaction in vivo and elucidation
of the novel CrV2 mode-of-action will likely be useful in
understanding themolecular signalingmechanisms in inver-
tebrate immunology. Such knowledge will be useful for
designing nontoxic, immune-related compounds for control
of pest insects.
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